Filtered By:
Condition: Heart Failure
Management: Hospitals
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 519 results found since Jan 2013.
Use of health and aged care services in Australia following hospital admission for myocardial infarction, stroke or heart failure
Cardiovascular diseases (CVD), including myocardial infarction (MI), stroke and heart failure (HF) are the leading cause of death amongst the older population worldwide. The aim of this study is to investigate...
Source: BMC Geriatrics - October 11, 2021 Category: Geriatrics Authors: Benjumin Hsu, Rosemary J. Korda, Richard I. Lindley, Kirsty A. Douglas, Vasi Naganathan and Louisa R. Jorm Tags: Research Source Type: research
Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - October 10, 2021 Category: Cardiology Source Type: research
Understanding Coordinator Roles in Acute Stroke Care: A National Survey
Globally, stroke is a major contributor to death and disability.1 Evidence-based care in hospital after an acute stroke ensures improved survival and reduced disability, but care quality can vary.2,3 Clinical coordinators have an essential role in improving best-practice in trauma, cancer, diabetes, and heart failure conditions.4-7 Within stroke, coordinator roles are not new; in 1970, a study outlining the ‘Stroke Team’ model was published, which included a physician, nurse-coordinator and physical therapist.
Source: Journal of Stroke and Cerebrovascular Diseases - September 29, 2021 Category: Neurology Authors: Tara Purvis, Sandy Middleton, Anne W. Alexandrov, Monique F. Kilkenny, Skye Coote, Sarah Kuhle, Dominique A. Cadilhac Source Type: research
Inhaled Beta2-Agonists Increase In-Hospital Mortality in ICU Patients with Heart Failure
This study aimed to investigate whether inhaled B2As increased in-hospital mortality in ICU patients with HF.The Multiparameter Intelligent Monitoring in Intensive Care III database was initially searched to identify adult patients (≥ 18 years old) with HF in ICU. Then, patients using or not using inhaled B2As were matched using propensity score matching on a 1:1 basis to control for baseline confounders. In-hospital mortality was compared between the two groups, and logistic regression analysis was performed to assess the association between B2As and in-hospital mortality.The initial search retrieved 2345 eligible patie...
Source: International Heart Journal - September 21, 2021 Category: Cardiology Authors: Zexiong Li Yesheng Ling Qian Chen Bingyuan Wu Long Peng Xixiang Tang Jinlai Liu Suhua Li Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Concomitant left atrial appendage occlusion in patients undergoing cardiac surgery
AbstractThe Left Atrial Appendage Occlusion Study (LAAOS III) was a multicenter, randomized controlled trial that included patients undergoing cardiac surgery who also had atrial fibrillation. The trial recruited 4811 participants, of which 2400 patients were randomized to undergo left atrial appendage (LAA) occlusion surgery, while 2411 participants had isolated cardiac surgery. The aim of the study was to determine whether concomitant occlusion of the LAA prevents ischemic stroke or systemic embolism. The study also evaluated the efficacy and safety of concomitant LAA occlusion in patients undergoing cardiac surgery. The...
Source: Indian Journal of Thoracic and Cardiovascular Surgery - August 16, 2021 Category: Cardiovascular & Thoracic Surgery Source Type: research
Sustained Use of the Impella 5.0 Heart Pump Enables Bridge to Clinical Decisions in 34 Patients
Tex Heart Inst J. 2021 Jul 1;48(3):e207260. doi: 10.14503/THIJ-20-7260.ABSTRACTWe studied whether sustained hemodynamic support (>7 d) with the Impella 5.0 heart pump can be used as a bridge to clinical decisions in patients who present with cardiogenic shock, and whether such support can improve their outcomes. We retrospectively reviewed cases of patients who had Impella 5.0 support at our hospital from August 2017 through May 2019. Thirty-four patients (23 with cardiogenic shock and 11 with severely decompensated heart failure) underwent sustained support for a mean duration of 11.7 ± 9.3 days (range, ≤48 d). Of 2...
Source: Texas Heart Institute Journal - August 13, 2021 Category: Cardiology Authors: Daniel W Nelson Sakthi Sundararajan Evan Klein Lyle D Joyce Lucian A Durham David L Joyce Asim A Mohammed Source Type: research
